Market Place
Sourcing Support
Pluri Evaluate PLX-R18 Mass Production for Acute Radiation Syndrome
25 Nov 2024 //
GLOBENEWSWIRE
Pluri Partners with Bar-Ilan University for Cancer Immunotherapy
28 Oct 2024 //
GLOBENEWSWIRE
Pluri To Manufacture Kadimastem`s Cell Therapy Product Candidates
18 Jul 2024 //
GLOBENEWSWIRE
Pluri Announces €1 Million Agreement to Enhance Global Vegetable Supply
08 Jul 2024 //
GLOBENEWSWIRE
Pluri`s Ever After Foods Secures $10M For Cultivated Food Scaling
18 Jun 2024 //
PRESS RELEASE
Pluri`s Ever After Foods Secures $10M Investment For Cultivated Food Scalability
18 Jun 2024 //
GLOBENEWSWIRE
NIH Funds $1.4M For Pluri`s PLX-R18 Radiation Syndrome Research
06 Jun 2024 //
PRESS RELEASE
NIH Funds $1.4M For Pluri`s PLX-R18 Acute Radiation Syndrome Contract Year 2
06 Jun 2024 //
GLOBENEWSWIRE
Pluri, Wilk Collaborate On Commercial Breast Milk Food Production
20 May 2024 //
GLOBENEWSWIRE
Pluri Launches MAIT Cell Platform For Solid Tumor Cancer Treatment
02 May 2024 //
PRESS RELEASE
Pluri Launches MAIT Immunotherapy For Solid Tumors
02 May 2024 //
GLOBENEWSWIRE
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
18 Apr 2024 //
PRESS RELEASE
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
08 Apr 2024 //
GLOBENEWSWIRE
Pluri`s Business Verticals Gain Traction in Global Markets
28 Mar 2024 //
GLOBENEWSWIRE
Pluri Inc. Announces 1-for-8 Reverse Share Split
27 Mar 2024 //
GLOBENEWSWIRE
Pluri Addresses Coffee Challenges With Sustainable Cell-Based Solution
21 Mar 2024 //
PRESS RELEASE
Pluri`s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed
21 Mar 2024 //
GLOBENEWSWIRE
Engage with Pluri’s Talent: Exciting Conference Appearances Ahead
19 Mar 2024 //
PRESS RELEASE
Engage with Pluri`s Talent: Exciting Conference Appearances Ahead
19 Mar 2024 //
GLOBENEWSWIRE
Pluri`s Business Verticals Gain Traction In Global Markets
18 Mar 2024 //
PRESS RELEASE
Pluri Selected as CDMO by Remedy Cell for Cell-Free Drug Manufacturing
14 Mar 2024 //
PRESS RELEASE
Pluri Receives First Patent For 3D Bioreactor In Plant Cell Cultivation
11 Mar 2024 //
PRESS RELEASE
Pluri Receives First-Ever Patent Approval for 3D Bioreactor Technology
11 Mar 2024 //
GLOBENEWSWIRE
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
06 Mar 2024 //
GLOBENEWSWIRE
Pluri CEO Updates On Recent Achievements And 2024 Goals
28 Feb 2024 //
PRESS RELEASE
Pluri™s Innovation Across Various Industries
28 Feb 2024 //
GLOBENEWSWIRE
Pluri Launches Cell-Based Coffee To Counter Global Coffee Crisis
23 Jan 2024 //
PRESS RELEASE
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure
23 Jan 2024 //
GLOBENEWSWIRE
Pluri Launches Cell Therapy Contract Development and Manufacturing Organization
08 Jan 2024 //
GLOBENEWSWIRE
Pluri Launches Global Cell Therapy CDMO
08 Jan 2024 //
CONTRACT PHARMA
Pluri and Bar-Ilan University to Develop PLX Cells for Cocaine Addiction
21 Dec 2023 //
GLOBENEWSWIRE
Pluri™s PLX-R18 Reduces Need for Transfusions in a Phase I Study
16 Aug 2023 //
GLOBENEWSWIRE
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
13 Jul 2023 //
GLOBENEWSWIRE
U.S. National Institutes of Health to Fund $4.2M Contract for Development of Pluris PLX-R18
11 Jul 2023 //
GLOBENEWSWIRE
Cell Manufacturing Pioneer, Pluri , Unveils PluriMatrix: a Breakthrough System
27 Apr 2023 //
GLOBENEWSWIRE
Israel Ministry of Labor Names Pluri as Winner of Egalitarian Employment Award
13 Mar 2023 //
GLOBENEWSWIRE
Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market
15 Dec 2022 //
GLOBENEWSWIRE
Pluri CEO Issues Shareholder Update
25 Jul 2022 //
GLOBENEWSWIRE
Pluristem Tx Changes its Name to “Pluri Inc.” Reflecting Company’s Strategy
25 Jul 2022 //
GLOBENEWSWIRE
Pluristem Reports Topline Results from its PIII Study of Muscle Regeneration
13 Jul 2022 //
GLOBENEWSWIRE
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
28 Mar 2022 //
GLOBENEWSWIRE
Pluristem Releases PLX-R18 Hematology Phase I Study Results
23 Mar 2022 //
GLOBENEWSWIRE
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as CEO
08 Mar 2022 //
GLOBENEWSWIRE
Pluristem CEO Issues Shareholder Update
02 Mar 2022 //
GLOBENEWSWIRE
Pluristem Announce Closing of its Collaboration with Tnuva Group
24 Feb 2022 //
GLOBENEWSWIRE
Pluristem & Tnuva Launch Landmark Collaboration for Cultured Food Platform
10 Jan 2022 //
GLOBENEWSWIRE
Pluristem reports topline results from Covid-19 therapy trial
29 Dec 2021 //
CLINICALTRIALSARENA
Pluristem Says Primary Endpoint Not Reached in Phase 2 Studies of PLX-PAD Cells
28 Dec 2021 //
TRIALSITENEWS
Pluristem Completes Enrollment of Its Multinational Phase III Study
15 Nov 2021 //
GLOBENEWSWIRE
Pluristem Receives ApprovalGrant from Israel Innovation Authority to Develop
10 Nov 2021 //
GLOBENEWSWIRE
Pluristem CEO Issues Shareholder Update
22 Sep 2021 //
GLOBENEWSWIRE
Pluristem Brings ARDS Associated with COVID-19 PhII Studies to Clinical Readout
08 Jul 2021 //
GLOBENEWSWIRE
Pluristem reports positive topline Phase I results in innovative hematology
29 Apr 2021 //
GLOBENEWSWIRE
Pluristem Announces DMC Recommendation Following Interim Analysis
09 Dec 2020 //
GLOBENEWSWIRE
PLURISTEM TO PRESENT INITIAL RESULTS FROM ITS PHASE I HCT STUDY WITH PLX-R18
18 Nov 2020 //
PRESS RELEASE
Pluristem to conduct Phase II COVID-19 European trial in Israel
06 Oct 2020 //
SEEKING ALPHA
Pluristem Therapeutics up on insider buy
02 Oct 2020 //
SEEKINGALFA
Pluristem CEO Issues Shareholder Update
15 Sep 2020 //
BIOSPACE
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program Enabling Patient
27 Aug 2020 //
GLOBENEWSWIRE
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
19 Aug 2020 //
GLOBENEWSWIRE
